Biomakers
Buenos Aires, Argentina· Est.
Argentinian biotech Biomakers develops engineered biologics for oncology and immunology using a proprietary protein‑engineering platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $25M
AI Company Overview
Argentinian biotech Biomakers develops engineered biologics for oncology and immunology using a proprietary protein‑engineering platform.
OncologyImmunologyAutoimmune Disorders
Technology Platform
A proprietary protein‑engineering platform that merges directed evolution, computational design, and AI‑driven epitope mapping to create stable, high‑affinity biologics, ADCs, bispecifics, and engineered T‑cell therapies.
Opportunities
Securing strategic partnerships with global pharma could accelerate clinical development and provide market access for Biomakers’ engineered biologics.
Risk Factors
Heavy reliance on pre‑clinical data and limited funding pose significant execution risk, especially in a competitive biologics landscape.
Competitive Landscape
Biomakers competes with established biologics firms such as Amgen and Roche, but differentiates through its AI‑enhanced protein‑engineering platform and focus on niche oncology targets.